Page last updated: 2024-10-27

fluorouracil and Weight Reduction

fluorouracil has been researched along with Weight Reduction in 60 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
"Patients with no weight loss and/or preserved PS and with a limited disease extent appeared to obtain the greatest benefit from our irinotecan/5-FU/LV regimen, with acceptable toxicity."9.11Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005)
"The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood."7.85Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017)
"5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents."7.85Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017)
" The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis."7.81Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. ( Cardoso, VN; Carneiro, CM; Faria, AM; Ferreira, AV; Generoso, Sde V; Maioli, TU; Paiva, NC; Rodrigues, NM; Trindade, LM, 2015)
" In the present study, we investigated the role of NOX1 in the pathogenesis of intestinal mucositis induced by the cancer chemotherapeutic agent 5-fluorouracil (5-FU) in mice."7.78Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Amagase, K; Iimori, M; Iwata, K; Kato, S; Kitahara, Y; Matsuno, K; Takeuchi, K; Utsumi, D; Yabe-Nishimura, C; Yamanaka, N; Yasuda, M, 2012)
"PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models."7.74Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007)
"5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer."7.70Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998)
"Data from OGSG1003, a randomized phase-II trial comparing two regimens of neoadjuvant chemotherapy, cisplatin and fluorouracil plus Adriamycin and cisplatin and fluorouracil plus docetaxel, for locally advanced esophageal squamous cell carcinoma were used."5.69The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003. ( Aoyama, S; Doki, Y; Fujitani, K; Hamakawa, T; Hirao, M; Kimura, Y; Makino, T; Miyata, H; Motoori, M; Shiraishi, O; Sugimura, K; Takeno, A; Tanaka, K; Yamasaki, M; Yamashita, K; Yano, M; Yasuda, T, 2023)
"The ADEBAR trial compares a sequential chemotherapy consisting of epirubicin/cyclophosphamide followed by docetaxel to an epirubicin/5-fluorouracil/cyclophosphamide regimen in patients with lymph node-positive early breast cancer."5.27Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. ( Beckmann, MW; de Gregorio, N; Fasching, PA; Fehm, T; Friedl, TWP; Harbeck, N; Jäger, B; Janni, W; Jückstock, J; Mahner, S; Mohrmann, S; Mutschler, NS; Rack, B; Salmen, J; Schochter, F; Scholz, C; Weissenbacher, T; Widschwendter, P; Ziegler, C; Zwingers, T, 2018)
"Patients with no weight loss and/or preserved PS and with a limited disease extent appeared to obtain the greatest benefit from our irinotecan/5-FU/LV regimen, with acceptable toxicity."5.11Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials. ( Buzzi, F; Comella, P; De Cataldis, G; De Lucia, L; Farris, A; Filippelli, G; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Natale, D; Palmeri, S; Roselli, M; Tafuto, S, 2005)
"The chemotherapeutic agent 5-fluorouracil (5-FU) causes intestinal mucositis with severe diarrhoea, but the pathogenesis is not fully understood."3.85Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice. ( Amagase, K; Hamouda, N; Higuchi, K; Kato, S; Matsumoto, K; Oikawa, Y; Ozaki, T; Sano, T; Shimakawa, M, 2017)
"5-Fluorouracil (5-FU) has broadly been applied to treat colorectal cancer as one of the most effective chemotherapeutic agents."3.85Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model. ( Li, M; Liang, X; Liu, Z; Teng, N; Wang, X; Xie, W; Yang, Z; Zhang, Z, 2017)
" The objective of this study was to determine whether a diet with the addition of n-3 FA helps control the inflammation observed in 5-fluorouracil (5-FU) induced mucositis."3.81Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice. ( Cardoso, VN; Carneiro, CM; Faria, AM; Ferreira, AV; Generoso, Sde V; Maioli, TU; Paiva, NC; Rodrigues, NM; Trindade, LM, 2015)
" boulardii was not able to prevent the effects of experimental mucositis induced by 5- Fluorouracil."3.80Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice. ( Cardoso, VN; Carneiro, CM; de Melo Silva, B; de Vasconcelos Generoso, S; Dias, MN; Dos Santos Martins, F; Fernandes, SO; Maioli, TU; Paiva, NC, 2014)
" In the present study, we investigated the role of NOX1 in the pathogenesis of intestinal mucositis induced by the cancer chemotherapeutic agent 5-fluorouracil (5-FU) in mice."3.78Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. ( Amagase, K; Iimori, M; Iwata, K; Kato, S; Kitahara, Y; Matsuno, K; Takeuchi, K; Utsumi, D; Yabe-Nishimura, C; Yamanaka, N; Yasuda, M, 2012)
"PTHrP and IL-6 were found to be factors in the development of cachexia in a colon 26 cancer model, and capecitabine improved cancer cachexia by suppressing the plasma levels of IL-6 and PTHrP in colon 26 and Y cachectic models."3.74Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. ( Fujimoto-Ouchi, K; Mori, K; Onuma, E; Shirane, M; Tanaka, Y, 2007)
"5-Fluorouracil (FUra) modulated by leucovorin (LV) is active in the treatment of colorectal cancer."3.70Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer. ( Cao, S; Rustum, YM; Troutt, AB, 1998)
"The scheduling of antifolate antitumor agents, including the new multitargeted autofolate LY231514 (MTA), with 5-fluorouracil was explored in the human MX-1 breast carcinoma and human H460 and Calu-6 non-small cell lung carcinoma xenografts to assess antitumor activity and toxicity (body weight loss)."3.70Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. ( Amsrud, T; Chen, V; Forler, PA; Menon, K; Phares, VG; Shih, C; Teicher, BA, 2000)
" Administration of topical TGF-beta 3 prior to chemotherapy with 5-fluorouracil (5-FU) significantly reduced the severity of mucositis with respect to time, reduced chemotherapy-associated weight loss and increased survival."3.69Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. ( Brien, JP; Bruskin, AM; Haley, JD; Muska, AD; Rose, A; Sonis, ST; Van Vugt, AG, 1997)
"Juzen-taiho-to (JTT; [Shi-quan-da-bu-tang], a Japanese modified Chinese herbal prescription) in combination with an anticancer drug UFT (5-fluorouracil derivative) prevented the body weight loss and the induction of the colonic cancer in rats treated with a chemical carcinogen 1,2-dimethylhydrazine (DMH), and suppressed markedly the activity of thymidylate synthetase (TS) involved in the de novo pathway of pyrimidine synthesis in colonic cancer induced by DMH."3.68Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. ( Kasahara, N; Kato, T; Kawasaki, T; Kudo, H; Kuwa, K; Nakayama, T; Okamoto, R; Sakamoto, S; Suzuki, S, 1991)
"Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies."3.11Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306). ( Algül, H; Decker, T; Erickson, NT; Gesenhues, AB; Heinemann, V; Heintges, T; Höffkes, HG; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Lerch, MM; Link, H; Liu, L; Michl, M; Modest, DP; Moehler, M; Ricard, I; Scheithauer, W; Stintzing, S; Theurich, S; von Weikersthal, LF, 2022)
"Deleterious oral mucositis (OM) develops during radiotherapy (RT) or chemoradiotherapy for head-and-neck cancer (HNC) patients."2.77Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer. ( Chung, YL; Jen, YM; Lin, YH; Wang, LW; Yen, SH, 2012)
"5-Fluorouracil 225 mg/m2 was delivered as a continuous infusion on days 1 through 38."2.71Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. ( Bader, SB; Louie, J; Molendyk, J; Phillips, M; Regan, J; Ross, HJ; Ruzich, J; Seligman, M; Seung, SK; Skokan, L; Smith, JW; Soo, E, 2004)
"There was a higher risk of grade≥3 infection for weight loss at diagnosis (P=0."1.51[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status]. ( Bernadach, M; Biau, J; Dillies, AF; Durando, X; Kwiatkowski, F; Lapeyre, M; Miroir, J; Moreau, J; Pham-Dang, N; Saroul, N, 2019)
"The population pharmacokinetic model consisting of a two-compartment model with Michaelis-Menten elimination kinetics successfully characterized the individual and population predictions of the plasma concentration of 5-FU and provided credible parameter estimates."1.46Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats. ( Ito, Y; Kobuchi, S; Sakaeda, T, 2017)
"3%); alteration and complete recovery (31%) or sustained deterioration (45%), possibly due to inadequate chronotherapy dosing and/or timing."1.40The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy. ( Beau, J; Innominato, PF; Iurisci, I; Karaboue, A; Lévi, F; Madrid, JA; Moreau, T; Ortiz-Tudela, E; Rol, MA, 2014)
"Patients with stage IVA esophageal cancer treated with chemoradiotherapy between April 2003 and March 2009 were evaluated."1.39Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy. ( Anbai, A; Hashimoto, M; Jin, M; Koga, M; Motoyama, S; Shibata, H, 2013)
"Patients with metastatic colorectal cancer (n = 543) from an international phase 3 trial comparing FOLFOX2 with chronoFLO4 were categorized into 4 subgroups according to the occurrence of FWL or other clinically relevant toxicities during the initial 2 courses of chemotherapy."1.39Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. ( Bjarnason, GA; Carvalho, C; Focan, C; Garufi, C; Giacchetti, S; Iacobelli, S; Innominato, PF; Karaboué, A; Lévi, F; Moreau, T; Poncet, A; Smaaland, R; Spiegel, D; Tampellini, M; Tumolo, S, 2013)
"5-fluorouracil (5-FU) is a common cytotoxic agent used to treat solid tumors."1.37CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis. ( Cheng, Z; Di, J; Du, Y; Han, X; Jin, Z; Pan, Y; Wang, Y; Wang, Z; Wu, Z; Zhang, H; Zhang, P; Zheng, Q, 2011)
"All of the patients had squamous cell carcinoma."1.37Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. ( Ahn, SD; Choi, EK; Kim, JH; Kim, SB; Lee, SW; Lee, YS; Park, JW; Park, SI; Song, SY; Yoon, SM, 2011)
"CRP was associated with disease progression and factors reflecting nutritional depletion such as serum albumin, lymphocyte count and body weight loss ratio."1.35Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. ( Inoue, Y; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Tanaka, K; Toiyama, Y; Yokoe, T, 2008)
" However, it was repeatedly shown that the sequence of 5-FU followed by CDDP is more active and less toxic in tumor-bearing animals."1.33Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. ( Fujimoto, S, 2006)
"Isoliquiritigenin is a chalcone isolated from licorice and shallots."1.31Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma. ( Baba, M; Endo, H; Hamamoto, T; Joichi, Y; Kaneko, S; Morita, T; Nishino, H; Okada, Y; Okuyama, T; Tokue, A; Yamazaki, S, 2002)
" injection of 200 mg/kg WR-2721 at 5 min prior to the administration of this combination enabled us to increase the CBDCA dose from a nontoxic level of 45 mg/kg to a normally toxic dose of 60 mg/kg in non-tumor-bearing BALB/c mice while maintaining the 5FU dose at 100 mg/kg."1.28Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil. ( Peters, GJ; Treskes, M; van der Vijgh, WJ; van der Wilt, CL; van Laar, JA, 1992)

Research

Studies (60)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.67)18.7374
1990's15 (25.00)18.2507
2000's13 (21.67)29.6817
2010's29 (48.33)24.3611
2020's2 (3.33)2.80

Authors

AuthorsStudies
Aoyama, S2
Motoori, M2
Yamasaki, M2
Shiraishi, O2
Miyata, H2
Hirao, M2
Takeno, A2
Sugimura, K2
Makino, T2
Tanaka, K3
Hamakawa, T2
Yamashita, K2
Kimura, Y2
Fujitani, K2
Yasuda, T2
Yano, M2
Doki, Y2
Liu, L1
Erickson, NT1
Ricard, I1
von Weikersthal, LF1
Lerch, MM1
Decker, T1
Kiani, A1
Kaiser, F1
Heintges, T1
Kahl, C1
Kullmann, F1
Scheithauer, W1
Link, H1
Höffkes, HG1
Moehler, M1
Gesenhues, AB1
Theurich, S1
Michl, M1
Modest, DP1
Algül, H1
Stintzing, S1
Heinemann, V1
Holch, JW1
Hamouda, N1
Sano, T1
Oikawa, Y1
Ozaki, T1
Shimakawa, M1
Matsumoto, K1
Amagase, K2
Higuchi, K1
Kato, S2
Liu, Z1
Xie, W1
Li, M1
Teng, N1
Liang, X1
Zhang, Z1
Yang, Z1
Wang, X2
Yu, FJ1
Shih, HY1
Wu, CY1
Chuang, YS1
Lee, JY1
Li, HP1
Fang, PT1
Tsai, DL1
Chou, SH1
Wu, IC1
Mutschler, NS1
Scholz, C1
Friedl, TWP1
Zwingers, T1
Fasching, PA1
Beckmann, MW1
Fehm, T1
Mohrmann, S1
Salmen, J1
Ziegler, C1
Jäger, B1
Widschwendter, P1
de Gregorio, N1
Schochter, F1
Mahner, S1
Harbeck, N1
Weissenbacher, T1
Jückstock, J1
Janni, W1
Rack, B1
Kao, CT1
Aziz, M1
Kasi, A1
Bernadach, M1
Lapeyre, M1
Dillies, AF1
Miroir, J1
Moreau, J1
Kwiatkowski, F1
Pham-Dang, N1
Saroul, N1
Durando, X1
Biau, J1
Neely, D1
Ong, J1
Patterson, J1
Kirkpatrick, D1
Skelly, R1
Innominato, PF2
Giacchetti, S1
Moreau, T2
Bjarnason, GA1
Smaaland, R1
Focan, C1
Garufi, C1
Iacobelli, S1
Tampellini, M1
Tumolo, S1
Carvalho, C1
Karaboué, A2
Poncet, A1
Spiegel, D1
Lévi, F2
Olson, R1
Karam, I1
Wilson, G1
Bowman, A1
Lee, C1
Wong, F1
Yao, Q1
Ye, X1
Wang, L1
Gu, J1
Fu, T1
Wang, Y3
Lai, Y1
Jin, H1
Guo, Y1
Ortiz-Tudela, E1
Iurisci, I1
Beau, J1
Rol, MA1
Madrid, JA1
Maioli, TU2
de Melo Silva, B1
Dias, MN1
Paiva, NC2
Cardoso, VN2
Fernandes, SO1
Carneiro, CM2
Dos Santos Martins, F1
de Vasconcelos Generoso, S1
Rivera, F1
Massutí, B1
Salcedo, M1
Sastre, J1
Martínez Galán, J1
Valladares-Ayerbes, M1
Serrano, R1
García de Paredes, ML1
Manzano, JL1
Galán, M1
Alsina, M1
Yuste Izquierdo, AL1
López, C1
Díaz-Rubio, E1
Conde, V1
Reboredo, M1
Cano, MT1
Pachón, V1
Aranda, E1
Generoso, Sde V1
Rodrigues, NM1
Trindade, LM1
Ferreira, AV1
Faria, AM1
Kobuchi, S1
Ito, Y1
Sakaeda, T1
Koike, Y1
Miki, C1
Okugawa, Y1
Yokoe, T2
Toiyama, Y1
Inoue, Y1
Kusunoki, M1
Dintinjana, RD1
Guina, T1
Krznarić, Z1
Radić, M1
Dintinjana, M1
Ersoy, E1
Akbulut, H1
Moray, G1
Buiret, G1
Combe, C1
Favrel, V1
Pommier, P1
Martin, L1
Ecochard, R1
Fayette, J1
Tartas, S1
Ramade, A1
Céruse, P1
Janelsins, MC1
Roscoe, JA1
Berg, MJ1
Thompson, BD1
Gallagher, MJ1
Morrow, GR1
Heckler, CE1
Jean-Pierre, P1
Opanashuk, LA1
Gross, RA1
Clavel, S1
Fortin, B1
Després, P1
Donath, D1
Soulières, D1
Khaouam, N1
Charpentier, D1
Bélair, M1
Guertin, L1
Nguyen-Tan, PF1
Park, JW1
Kim, JH1
Choi, EK1
Lee, SW1
Yoon, SM1
Song, SY1
Lee, YS1
Kim, SB1
Park, SI1
Ahn, SD1
Prestwich, RJ1
Öksüz, DÇ1
Dyker, K1
Coyle, C1
Şen, M1
Han, X1
Wu, Z1
Di, J1
Pan, Y1
Zhang, H1
Du, Y1
Cheng, Z1
Jin, Z1
Wang, Z1
Zheng, Q1
Zhang, P1
Yen, SH1
Wang, LW1
Lin, YH1
Jen, YM1
Chung, YL1
Chou, TC1
Dong, H1
Zhang, X1
Lei, X1
Hartung, J1
Zhang, Y1
Lee, JH1
Wilson, RM1
Danishefsky, SJ1
Ramachandran, S1
Mandal, M1
Bonatto, SJ1
Oliveira, HH1
Nunes, EA1
Pequito, D1
Iagher, F1
Coelho, I1
Naliwaiko, K1
Kryczyk, M1
Brito, GA1
Repka, J1
Sabóia, LV1
Fukujima, G1
Calder, PC1
Fernandes, LC1
Yasuda, M1
Yamanaka, N1
Iimori, M1
Utsumi, D1
Kitahara, Y1
Iwata, K1
Matsuno, K1
Yabe-Nishimura, C1
Takeuchi, K1
Tomita, M1
Matsuyama, H1
Yamazaki, K1
Sato, K1
Takahashi, S1
Peerawong, T1
Phungrassami, T1
Pruegsanusak, K1
Sangthong, R1
Anbai, A1
Koga, M1
Motoyama, S1
Jin, M1
Shibata, H1
Hashimoto, M1
Tebbutt, NC2
Norman, A2
Cunningham, D3
Iveson, T1
Seymour, M1
Hickish, T1
Harper, P1
Maisey, N1
Mochlinski, K1
Prior, Y1
Hill, M2
Kelleher, M1
Andreyev, J1
Allen, M1
Seung, SK1
Smith, JW1
Molendyk, J1
Bader, SB1
Phillips, M1
Regan, J1
Louie, J1
Soo, E1
Seligman, M1
Ruzich, J1
Skokan, L1
Ross, HJ1
Lin, A1
Jabbari, S1
Worden, FP1
Bradford, CR1
Chepeha, DB1
Teknos, TN1
Liao, JJ1
Nyquist, GG1
Tsien, C1
Schipper, MJ1
Urba, S1
Wolf, GT1
Eisbruch, A1
Comella, P1
Massidda, B1
Filippelli, G1
Natale, D1
Farris, A1
Buzzi, F1
Tafuto, S1
Maiorino, L1
Palmeri, S1
De Lucia, L1
Mancarella, S1
Leo, S1
Roselli, M1
Lorusso, V1
De Cataldis, G1
Fujimoto-Ouchi, K1
Onuma, E1
Shirane, M1
Mori, K1
Tanaka, Y1
Fujimoto, S1
Le Bricon, T1
Gugins, S1
Cynober, L1
Baracos, VE1
Sonis, S1
Muska, A1
O'Brien, J1
Van Vugt, A1
Langer-Safer, P1
Keith, J2
Galandiuk, S1
Wrightson, W1
Marr, L1
Myers, S1
LaRocca, RV1
Van Laar, JA3
Rustum, YM2
Van der Wilt, CL3
Smid, K2
Kuiper, CM1
Pinedo, HM1
Peters, GJ3
Prott, FJ1
Schönekaes, K1
Preusser, P1
Ostkamp, K1
Wagner, W1
Micke, O1
Pötter, R1
Sulkowski, U1
Rübe, C1
Berns, T1
Willich, N1
Sonis, ST2
Van Vugt, AG2
Brien, JP1
Muska, AD1
Bruskin, AM1
Rose, A1
Haley, JD1
McDonald, J1
Dotoli, E1
Schwertschlag, U1
Szklut, P1
Cao, S1
Troutt, AB1
Andreyev, HJ1
Norman, AR1
Oates, J1
Arikan, AY1
Senel, FM1
Akman, RY1
Can, C1
Teicher, BA1
Chen, V1
Shih, C1
Menon, K1
Forler, PA1
Phares, VG1
Amsrud, T1
Jian, JJ1
Cheng, SH1
Tsai, SY1
Yen, KC1
Chu, NM1
Chan, KY1
Tan, TD1
Cheng, JC1
Lin, YC1
Leu, SY1
Hsieh, CI1
Tsou, MH1
Lin, CY1
Huang, AT1
Yamazaki, S1
Morita, T1
Endo, H1
Hamamoto, T1
Baba, M1
Joichi, Y1
Kaneko, S1
Okada, Y1
Okuyama, T1
Nishino, H1
Tokue, A1
Gyergyay, F1
Treskes, M1
van der Vijgh, WJ1
Iino, Y1
Yoshida, M1
Sugamata, N1
Maemura, M1
Ohwada, S1
Ishikita, T1
Horiuchi, R1
Morishita, Y1
de Roy van Zuidewijn, DB1
Hendriks, T1
Wobbes, T1
de Boer, HH1
Sakamoto, S1
Kudo, H1
Kuwa, K1
Suzuki, S1
Kato, T1
Kawasaki, T1
Nakayama, T1
Kasahara, N1
Okamoto, R1
Allum, WH1
Hallissey, MT1
Kelly, KA1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480]Phase 263 participants (Actual)Interventional2020-02-01Completed
Phase II Study of Adjusted-dose Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status.[NCT00733616]Phase 244 participants (Actual)Interventional2008-11-30Completed
A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372]196 participants (Anticipated)Interventional2016-11-30Recruiting
Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540]Phase 3210 participants (Anticipated)Interventional2014-10-31Recruiting
Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615]Phase 360 participants (Anticipated)Interventional2014-10-31Recruiting
[NCT02603159]Phase 3200 participants (Anticipated)Interventional2014-10-31Recruiting
Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036]Phase 3249 participants (Actual)Interventional2014-10-31Active, not recruiting
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy[NCT02644408]Phase 3184 participants (Actual)Interventional2014-10-01Completed
Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897]Phase 240 participants (Actual)Interventional2018-10-25Completed
Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.[NCT02456506]142 participants (Anticipated)Interventional2015-06-30Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for fluorouracil and Weight Reduction

ArticleYear
Small intestinal adenocarcinoma: rarely considered, often missed?
    Postgraduate medical journal, 2013, Volume: 89, Issue:1050

    Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do

2013
Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
    British journal of cancer, 1997, Volume: 75, Issue:4

    Topics: Adenocarcinoma; Aged; Antidotes; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease

1997

Trials

11 trials available for fluorouracil and Weight Reduction

ArticleYear
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
The impact of weight loss during neoadjuvant chemotherapy on postoperative infectious complications and prognosis in patients with esophageal cancer: exploratory analysis of OGSG1003.
    Esophagus : official journal of the Japan Esophageal Society, 2023, Volume: 20, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neop

2023
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).
    International journal of cancer, 2022, 01-01, Volume: 150, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorect

2022
Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study.
    Clinical breast cancer, 2018, Volume: 18, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuv

2018
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast

2015
Phenylbutyrate mouthwash mitigates oral mucositis during radiotherapy or chemoradiotherapy in patients with head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2012, Mar-15, Volume: 82, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Double-Blind Method; E

2012
Fish oil supplementation improves neutrophil function during cancer chemotherapy.
    Lipids, 2012, Volume: 47, Issue:4

    Topics: Antineoplastic Agents; Brazil; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fe

2012
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2002
Mitomycin C, carboplatin and protracted venous infusion 5-fluorouracil in advanced oesophago-gastric and pancreatic cancer: results of two phase II studies.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Esophageal Neoplasms; Fema

2003
Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free

2004
Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of two consecutive southern Italy cooperative oncology group trials.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptot

2005
Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.
    Lancet (London, England), 1989, Mar-18, Volume: 1, Issue:8638

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy

1989

Other Studies

47 other studies available for fluorouracil and Weight Reduction

ArticleYear
Apoptosis, Dysbiosis and Expression of Inflammatory Cytokines are Sequential Events in the Development of 5-Fluorouracil-Induced Intestinal Mucositis in Mice.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 121, Issue:3

    Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cyto

2017
Oral Administration of Polaprezinc Attenuates Fluorouracil-induced Intestinal Mucositis in a Mouse Model.
    Basic & clinical pharmacology & toxicology, 2017, Volume: 121, Issue:6

    Topics: Animals; Anti-Ulcer Agents; Antimetabolites, Antineoplastic; Carnosine; Cell Proliferation; Colorect

2017
Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding.
    Gastrointestinal endoscopy, 2018, Volume: 88, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutiti

2018
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
    BMJ case reports, 2018, Sep-01, Volume: 2018

    Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th

2018
[Toxicity of docetaxel, platine, 5-fluorouracil-based induction chemotherapy for locally advanced head and neck cancer: The importance of nutritional status].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2019, Volume: 23, Issue:4

    Topics: Adult; Age Factors; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetax

2019
Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer.
    Cancer, 2013, Jul-15, Volume: 119, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progressi

2013
Population-based comparison of two feeding tube approaches for head and neck cancer patients receiving concurrent systemic-radiation therapy: is a prophylactic feeding tube approach harmful or helpful?
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:12

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin

2013
Protective effect of curcumin on chemotherapy-induced intestinal dysfunction.
    International journal of clinical and experimental pathology, 2013, Volume: 6, Issue:11

    Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Biomarkers;

2013
The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.
    International journal of cancer, 2014, Jun-01, Volume: 134, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circad

2014
Pretreatment with Saccharomyces boulardii does not prevent the experimental mucositis in Swiss mice.
    Journal of negative results in biomedicine, 2014, Apr-11, Volume: 13

    Topics: Animals; Antimetabolites, Antineoplastic; Feeding Behavior; Fluorouracil; Intestinal Mucosa; Mice; M

2014
Dietary supplementation with omega-3 fatty acid attenuates 5-fluorouracil induced mucositis in mice.
    Lipids in health and disease, 2015, Jun-12, Volume: 14

    Topics: Animals; Apoptosis; Dietary Supplements; Escherichia coli; Fatty Acids, Omega-3; Fluorouracil; Ileum

2015
Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
    European journal of drug metabolism and pharmacokinetics, 2017, Volume: 42, Issue:4

    Topics: Administration, Intravenous; Animals; Antimetabolites, Antineoplastic; Blood Cell Count; Dose-Respon

2017
Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
    Journal of surgical oncology, 2008, Dec-01, Volume: 98, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Prote

2008
Effects of nutritional support in patients with colorectal cancer during chemotherapy.
    Collegium antropologicum, 2008, Volume: 32, Issue:3

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Body Mass Index; Camptothecin; Color

2008
Effects of oxaliplatin and 5-fluorouracil on the healing of colon anastomoses.
    Surgery today, 2009, Volume: 39, Issue:1

    Topics: Anastomosis, Surgical; Animals; Antineoplastic Agents; Colonic Neoplasms; Disease Models, Animal; Fe

2009
A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
    International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot

2010
IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice.
    Cancer investigation, 2010, Volume: 28, Issue:5

    Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Bromodeoxyuridine; Cell Proliferation; Cyclopho

2010
Enteral feeding during chemoradiotherapy for advanced head-and-neck cancer: a single-institution experience using a reactive approach.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squa

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma,

2011
Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
    International journal of radiation oncology, biology, physics, 2011, Nov-15, Volume: 81, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiothe

2011
CXCL9 attenuated chemotherapy-induced intestinal mucositis by inhibiting proliferation and reducing apoptosis.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2011, Volume: 65, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Chemokine CXCL9; Diarrhea;

2011
Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol.
    Proceedings of the National Academy of Sciences of the United States of America, 2011, Aug-23, Volume: 108, Issue:34

    Topics: Animals; Biological Products; Cell Death; Cytoprotection; Enediynes; Fatty Alcohols; Female; Fluorou

2011
Induction of apoptosis of azurin synthesized from P. aeruginosa MTCC 2453 against Dalton's lymphoma ascites model.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2011, Volume: 65, Issue:7

    Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Pro

2011
Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice.
    American journal of physiology. Gastrointestinal and liver physiology, 2012, May-15, Volume: 302, Issue:10

    Topics: Animals; Antimetabolites, Antineoplastic; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase

2012
[Concurrent chemoradiotherapy with either CDDP or CDGP, plus 5-FU for squamous cell carcinoma of the oropharynx and hypopharynx].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2012
Comparison of treatment compliance and nutritional outcomes among patients with nasopharyngeal carcinoma with and without percutaneous endoscopic gastrostomy during chemoradiation.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Squamous Cell; Ci

2012
Outcomes of patients with stage IVA esophageal cancer (Japanese classification) treated with definitive chemoradiotherapy.
    Japanese journal of radiology, 2013, Volume: 31, Issue:4

    Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemoradiotherapy;

2013
Metabolic abnormalities associated with weight loss during chemoirradiation of head-and-neck cancer.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Cisplatin

2005
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:6

    Topics: Animals; Cachexia; Capecitabine; Cell Line; Colonic Neoplasms; Deoxycytidine; Fluorouracil; Hypercal

2007
Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
    Biological & pharmaceutical bulletin, 2006, Volume: 29, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin

2006
Negative impact of cancer chemotherapy on protein metabolism in healthy and tumor-bearing rats.
    Metabolism: clinical and experimental, 1995, Volume: 44, Issue:10

    Topics: Animals; Antineoplastic Agents; Cachexia; Cisplatin; Cyclophosphamide; DNA; Eating; Female; Fluorour

1995
Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11.
    European journal of cancer. Part B, Oral oncology, 1995, Volume: 31B, Issue:4

    Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cricetinae; Dose-Response Relationship, Drug;

1995
Suppository delivery of 5-fluorouracil in rectal cancer.
    Annals of surgical oncology, 1996, Volume: 3, Issue:3

    Topics: Administration, Rectal; Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liqu

1996
Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
    Cancer chemotherapy and pharmacology, 1996, Volume: 39, Issue:1-2

    Topics: Adenocarcinoma; Animals; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot

1996
Transforming growth factor-beta 3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis.
    Oral oncology, 1997, Volume: 33, Issue:1

    Topics: Administration, Topical; Animals; Antimetabolites, Antineoplastic; Biomarkers; Cell Division; Cricet

1997
Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters.
    Cytokine, 1997, Volume: 9, Issue:8

    Topics: Animals; Blood Cell Count; Bone Marrow Cells; Cricetinae; Fluorouracil; Interleukin-11; Male; Mesocr

1997
Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer.
    Cancer research, 1998, Apr-15, Volume: 58, Issue:8

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Female; Flu

1998
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino

1998
Comparison of the effects of various anticancer agents on intestinal anastomosis after intraperitoneal administration.
    Surgery today, 1999, Volume: 29, Issue:8

    Topics: Analysis of Variance; Anastomosis, Surgical; Animals; Antimetabolites, Antineoplastic; Antineoplasti

1999
Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, N

2000
Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy.
    International journal of radiation oncology, biology, physics, 2002, Jun-01, Volume: 53, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D

2002
Isoliquiritigenin suppresses pulmonary metastasis of mouse renal cell carcinoma.
    Cancer letters, 2002, Sep-08, Volume: 183, Issue:1

    Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Chalcone; Chalcones; Dose-Response Relationsh

2002
Biochemical modification of the toxicity and the anti-tumour effect of 5-fluorouracil and cis-platinum by WR-2721 in mice.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:12

    Topics: Amifostine; Animals; Cisplatin; Colonic Neoplasms; Female; Fluorouracil; Leukopenia; Mice; Mice, Inb

1992
Effect of WR-2721 on the toxicity and antitumor activity of the combination of carboplatin and 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1992, Volume: 31, Issue:2

    Topics: Amifostine; Anemia; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Ne

1992
1 alpha-hydroxyvitamin D3, hypercalcemia, and growth suppression of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
    Breast cancer research and treatment, 1992, Volume: 22, Issue:2

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Divi

1992
Intraperitoneal cytostatics impair healing of experimental intestinal anastomoses.
    British journal of cancer, 1991, Volume: 63, Issue:6

    Topics: Anastomosis, Surgical; Animals; Bleomycin; Body Weight; Cisplatin; Colon; Fluorouracil; Hydroxyproli

1991
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats.
    The American journal of Chinese medicine, 1991, Volume: 19, Issue:3-4

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eva

1991